You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 17, 2026

Regulatory Exclusivity: NEW INDICATION


✉ Email this page to a colleague

« Back to Dashboard


Drugs with New Indication Regulatory Exclusivity

Click here to exclude patents covering these drugs from this list

Glossary
Applicant Tradename Generic Name NDA Approval Date Type Patent No. Patent Expiration Exclusivity Expiration Patented / Exclusive Use
Incyte Corp OPZELURA ruxolitinib phosphate 215309 Sep 21, 2021 RX 12,233,067 ⤷  Start Trial ⤷  Start Trial INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
Incyte Corp OPZELURA ruxolitinib phosphate 215309 Sep 21, 2021 RX 11,510,923 ⤷  Start Trial ⤷  Start Trial INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
Incyte Corp OPZELURA ruxolitinib phosphate 215309 Sep 21, 2021 RX 11,602,536 ⤷  Start Trial ⤷  Start Trial INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
Incyte Corp OPZELURA ruxolitinib phosphate 215309 Sep 21, 2021 RX 11,590,138 ⤷  Start Trial ⤷  Start Trial INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
Incyte Corp OPZELURA ruxolitinib phosphate 215309 Sep 21, 2021 RX 11,590,137 ⤷  Start Trial ⤷  Start Trial INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
>Applicant >Tradename >Generic Name >NDA >Approval Date >Type >Patent No. >Patent Expiration >Exclusivity Expiration >Patented / Exclusive Use

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links